Format

Send to

Choose Destination
Pediatr Blood Cancer. 2012 Aug;59(2):372-6. doi: 10.1002/pbc.24177. Epub 2012 Apr 27.

Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease.

Author information

1
Dipartimento di Ematologia ed Oncologia Pediatrica, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy. franco.locatelli@opbg.net

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment for sickle cell disease (SCD), being successful in around 85-90% of patients. Mortality and long-term morbidity (including infertility, gonadal failure, and chronic graft-vs.-host disease) associated with conventional approaches curtail the number of patients who undergo allo-HSCT. Recently, it has been demonstrated that cord blood is as effective as and possibly safer than bone marrow in pediatric patients with SCD. Likewise, transplant strategies based on the use of reduced-intensity regimens and the induction of mixed chimerism have been explored to decrease allo-HSCT short- and long-term complications.

PMID:
22544533
DOI:
10.1002/pbc.24177
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center